针对DPP-4的合理设计的小:强效抗糖尿病药物的鉴定
Sombir Jaglan1, Palwinder Singh1, Sheetal Vermani1
1Department of Chemistry, Guru Nanak Dev University, Amritsar 143005, India.
Bioorganic chemistry
|July 23, 2025
概括
研究人员开发了针对二二酶-4 (DPP-4) 的基于的新型抑制剂,用于治疗2型糖尿病. 化合物8显示出强大的DPP-4抑制,并有效降低糖尿病大鼠的血糖.
科学领域:
- 药用化学 医学化学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抑制二乙酶-4 (DPP-4) 是治疗2型糖尿病的一个关键策略.
- 开发新型,强效和安全的DPP-4抑制剂仍然是研究的一个活跃领域.
研究的目的:
- 设计和合成新的基于的DPP-4抑制剂.
- 评估合成化合物作为抗糖尿病药物的体外和体内疗效和安全性.
主要方法:
- 18种基于的DPP-4抑制剂的合成和表征.
- 在体外酶抑制试验测试以确定IC50值.
- 在体内研究中,使用链子/尼古丁胺胺诱导的糖尿病Wistar大鼠.
- 对药物动力学 (ADME) 和安全性概况的评估.
- 分子对接和结合能量的计算 (MM-GBSA) 用于选择性分析.
主要成果:
- 化合物8表现出显著的DPP-4抑制活性,IC50为0.12nM.
- 化合物8表现出有利的药物相似性,包括良好的溶解性和血稳定性.
- 化合物8在体内给药使糖尿病大鼠的葡萄糖水平正常化,脂质样本,肝酶和参数得到改善.
- 组织病理学分析证实了化合物8对脏和胰腺组织的保护作用.
- 化合物8对DPP-4比相关蛋白酶DPP-8和DPP-9具有很高的选择性,这是由结合能量的计算表明的.
结论:
- 基于的DPP-4抑制剂代表了对2型糖尿病的有前途的治疗方法.
- 化合物8是一种强效和选择性的DPP-4抑制剂,具有显著的抗糖尿病作用和有利的安全性.
- 对化合物8进行进一步的研究是为其作为一种新型抗糖尿病药物的临床开发而有必要的.
相关概念视频
Glucagon-like Receptor Agonists
421
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
421
Dipeptidyl Peptidase 4 Inhibitors
262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262
Oral Hypoglycemic Agents: Biguanides and Glitazones
305
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
305
Insulin: Biosynthesis, Chemistry, and Preparation
560
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
560
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
265
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
265
Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263


